BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 14871851)

  • 1. Potent antitumor activity of interleukin-27.
    Hisada M; Kamiya S; Fujita K; Belladonna ML; Aoki T; Koyanagi Y; Mizuguchi J; Yoshimoto T
    Cancer Res; 2004 Feb; 64(3):1152-6. PubMed ID: 14871851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27.
    Morishima N; Owaki T; Asakawa M; Kamiya S; Mizuguchi J; Yoshimoto T
    J Immunol; 2005 Aug; 175(3):1686-93. PubMed ID: 16034109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
    Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
    Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.
    Chiyo M; Shimozato O; Yu L; Kawamura K; Iizasa T; Fujisawa T; Tagawa M
    Int J Cancer; 2005 Jun; 115(3):437-42. PubMed ID: 15688376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lineage-specific requirement for signal transducer and activator of transcription (Stat)4 in interferon gamma production from CD4(+) versus CD8(+) T cells.
    Carter LL; Murphy KM
    J Exp Med; 1999 Apr; 189(8):1355-60. PubMed ID: 10209051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
    Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
    J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells.
    Wang YQ; Ugai S; Shimozato O; Yu L; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Tagawa M
    Int J Cancer; 2003 Jul; 105(6):820-4. PubMed ID: 12767068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
    Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
    J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells.
    Afkarian M; Sedy JR; Yang J; Jacobson NG; Cereb N; Yang SY; Murphy TL; Murphy KM
    Nat Immunol; 2002 Jun; 3(6):549-57. PubMed ID: 12006974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.
    Narvaiza I; Mazzolini G; Barajas M; Duarte M; Zaratiegui M; Qian C; Melero I; Prieto J
    J Immunol; 2000 Mar; 164(6):3112-22. PubMed ID: 10706701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
    Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
    Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts.
    Ugai S; Shimozato O; Kawamura K; Wang YQ; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Mar; 10(3):187-92. PubMed ID: 12637939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
    Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
    Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet.
    Lin JT; Martin SL; Xia L; Gorham JD
    J Immunol; 2005 May; 174(10):5950-8. PubMed ID: 15879087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells.
    Xiang J; Chen Z; Huang H; Moyana T
    Leuk Res; 2001 Oct; 25(10):909-15. PubMed ID: 11532525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
    Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.